Relapsing Multiple Sclerosis
Conditions
Keywords
COVID-19, vaccine, ofatumumab, SARS-coV2, antibody, open-label
Brief summary
This is a single arm, pilot multicenter prospective study in up to 22 participants with relapsing multiple sclerosis. Patients screened for the study can either be scheduled for vaccine, have received a single vaccine with a scheduled second dose, or already completed full course (two dose) vaccination. Fully vaccinated participants must be able to complete immune assay No.1 ≥ 14 days after the second dose of vaccine
Interventions
OTHEROfatumumab
Prospective observational cohort study. There is no treatment allocation. Patients administered Ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
OTHERCovid-19 vaccine
Prospective observational cohort study. There is no treatment allocation. Participants will obtain the COVID-19 FDA approved Emergency Use mRNA vaccine through their HCP (private insurance) or appropriate federal, state or local program.
Sponsors
Novartis Pharmaceuticals
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
1. Signed informed consent must be obtained prior to participation in the study 2. Age 18-55 years old inclusive at Screening 3. Diagnosis of relapsing MS by 2017 revised McDonald criteria 4. Must be willing to comply with the study schedule 5. Have received/scheduled vaccination with a FDA approved for emergency use COVID-19 mRNA vaccine (either Pfizer or Moderna) (i) either been scheduled for vaccine, (ii) received a single vaccine with a scheduled second dose, or (iii) already completed full course (two dose) vaccination. 6. Currently receiving ofatumumab for the treatment of RMS (Preoftumumab serology with Hepatitis B testing showing no active or latent infection, as well as serum IgG results to be recorded in the database if available)
Exclusion criteria
1. Known clinical diagnosis of COVID-19 prior to screening based on investigator's or patient's personal physician's judgement 2. Has a contraindication to receiving an mRNA COVID-19 vaccine 3. Has an immediate allergic reaction to past vaccine or injection 4. Any safety finding including low IgG and/or low IgM levels requiring an ofatumumab treatment interruption within the 12 weeks immediately prior to vaccination as determined by the HCP 5. Any major episode of infection requiring hospitalization or treatment with intravenous antibiotics within 2 weeks prior to the screening visit 6. Prior treatment with S1P agent within 2 months of study enrollment 7. Prior treatment with natalizumab within 6 months of study enrollment 8. Contraindications to ofatumumab treatment as per the USPI will be adhered to which include active infection hepatitis B infection, progressive multifocal leukoencephalopathy and pregnancy. 9. Participation in another interventional clinical trial within 14 days before enrollment. 10. Have been treated with any of the medications as described in the full protocol 11. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment and for 6 months after stopping medication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of participants achieving immune response - immune assay No. 1 | 14 days after full course vaccination (two doses) | Achieving immune response as defined by a positive SARS-CoV-2 qualitative IgG antibody assay. (yes/no) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of participants achieving immune response - immune assay No. 2 | 90 days post assay 1 | Achieving immune response as defined by a positive SARS-CoV-2 qualitative IgG antibody assay 90 days after assay No. 1 (yes/no) |
| Adverse events/serious adverse events | 120 days after full course vaccination | An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. |
Countries
Puerto Rico, United States
Outcome results
None listed